Mitoguazone

• CAT Number: I007998
• CAS Number: 459-86-9
• Molecular Formula: C5H12N8
• Molecular Weight: 184.2
• Purity: ≥95%
• Solubility: Soluble in DMSO, not in water
• Storage: Store at -20°C
• IUPAC Name: 2-[(E)-[(1E)-1-(diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine
• InChI: InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+
• InChIKey: MXWHMTNPTTVWDM-NXOFHUPFSA-N
• SMILES: CC(=NN=C(N)N)C=NN=C(N)N

Mitoguazone (Cat No.:I007998) is a synthetic polycarbonate derivative with potent antitumor activity. Mitoguazone is a blood-brain barrier-permeable competitive S-adenosyl-methionine decarboxylase inhibitor that disrupts polyamine biosynthesis. Mitoguazone induces apoptosis and inhibits HIV DNA integration into cellular DNA in monocytes and macrophages. Mitoguazone can be used in the research of acute leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma.

Reference

1:Administration of the antitumor drug mitoguazone protects normal thymocytes against spontaneous and etoposide-induced apoptosis. Ferioli ME, Bottone MG, Soldani C, Pellicciari C.Cell Mol Life Sci. 2004 Nov;61(21):2767-73. PMID: 15549180 2:Effect of mitoguazone on polyamine oxidase activity in rat liver. Ferioli ME, Berselli D, Caimi S.Toxicol Appl Pharmacol. 2004 Dec 1;201(2):105-11. PMID: 15541750 3:Treatment of AIDS related non-Hodgkin/’s lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study. Tulpule A, Espina BM, Pedro Santabarbara AB, Palmer M, Schiflett J, Boswell W, Smith S, Levine AM.Invest New Drugs. 2004 Jan;22(1):63-8. PMID: 14707495 4:A phase I human trial of mitoguazone and gemcitabine sequential bi-weekly treatment of cancer patients. Ishmael DR, Chen WR, Hamilton SA, Liu H, Nordquist RE.Cancer Invest. 2003;21(4):542-9. PMID: 14533444 5:Rapid and sensitive quantitation of the antiproliferative agent mitoguazone in small volumes of plasma by high-performance liquid chromatography with ultraviolet detection. Cheng CL, Lin EG, Chou CH.J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Aug 15;793(2):281-9. PMID: 12906902 6:Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors. Ishmael DR, Chen WR, Nordquist JA, Liu H, Nordquist RE.Cancer Invest. 2003 Apr;21(2):217-26. PMID: 12743987 7:Polyamine oxidase activity in rats treated with mitoguazone: specific and permanent decrease in thymus. Ferioli ME, Armanni A.Amino Acids. 2003;24(1-2):187-94. PMID: 12624752 8:Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G.Eur J Haematol Suppl. 2001 Jul;64:14-20. PMID: 11486395 9:Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: a phase II study (P-H482) of the Eastern Cooperative Oncology Group. Wiernik PH, Gordon LI, Oken MM, Harris JE, O/’Connell MJ.Leuk Lymphoma. 1999 Oct;35(3-4):375-7. PMID: 10706462 10:Mitoguazone induces apoptosis via a p53-independent mechanism. Davidson K, Petit T, Izbicka E, Koester S, Von Hoff DD.Anticancer Drugs. 1998 Aug;9(7):635-40. PMID: 9773808